On March 17, 2025, Enlivex Therapeutics Ltd. announced that a patent application for its Allocetra™ treatment method for osteoarthritis received approval from the China National Intellectual Property Administration, extending protection until at least 2040. This is a significant event as it enhances the company's intellectual property rights in China.